Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: I have 4 concerns about the
study by Dr Steinberg and colleagues.1 First,
the authors did not analyze the differences in outcomes between patients with
low vs high initial levels of hemoglobin F (HbF) that rose with hydroxyurea
treatment. Such an analysis would best assess the authors' hypothesis that
the hydroxyurea-induced rise in HbF confers hydroxyurea's beneficial effect
Hagar W. Long-term Use of Hydroxyurea for Sickle Cell AnemiaLong-term Use of Hydroxyurea for Sickle Cell Anemia. JAMA. 2003;290(6):752. doi:10.1001/jama.290.6.752-a
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: